levofloxacin has been researched along with Lupus Erythematosus, Systemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cui, Y; Guo, P; Guo, X; Shao, S | 1 |
| Argemi, X; Hansmann, Y; Keller, N; Martin, A; Martin, M; Martin, T; Twizeyimana, E | 1 |
| Amankwa, K; Krishnan, SC; Tisdale, JE | 1 |
1 review(s) available for levofloxacin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Roseomonas mucosa infective endocarditis in patient with systemic lupus erythematosus: case report and review of literature.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bacteremia; Endocarditis; Endocarditis, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Lupus Erythematosus, Systemic; Methylobacteriaceae; Piperacillin, Tazobactam Drug Combination | 2019 |
2 other study(ies) available for levofloxacin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
A non-fatal pneumonia due to Legionella longbeachae in a patient with systemic lupus erythematosus.
Topics: Adult; Female; Humans; Legionella longbeachae; Legionellosis; Levofloxacin; Lupus Erythematosus, Systemic; Pneumonia; Spiramycin; Treatment Outcome | 2016 |
Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
Topics: Aged; Cardiovascular Diseases; Female; Fluoroquinolones; Humans; Levofloxacin; Lupus Erythematosus, Systemic; Ofloxacin; Osteomyelitis; Risk Factors; Torsades de Pointes | 2004 |